NUMBERS HAVE POWER.
JOIN THE REGISTRY.
ADVANCE THE SCIENCE.
Together we can find a cure for ftd
The FTD Disorders Registry is a powerful tool in the movement to create therapies and find a cure. Together we can help change the course of the disease and put an end to FTD.
Your privacy is important! We promise to protect it. We will not share your contact information.
The Registry is an online database that collects information from those affected by all types of frontotemporal degeneration (FTD):
Persons diagnosed, current and former caregivers, family, and friends can join. As a member of the Registry, you can help us advance the science and move faster toward finding treatments and cures. The first step is simple:
NUMBERS HAVE POWER.
JOIN THE REGISTRY.
ADVANCE THE SCIENCE.
NUMBERS HAVE POWER.
JOIN THE REGISTRY.
ADVANCE THE SCIENCE.
Together we can find a cure for ftd
The FTD Disorders Registry is a powerful tool in the movement to create therapies and find a cure. Together we can help change the course of the disease and put an end to FTD.
Your privacy is important! We promise to protect it. We will not share your contact information.
The Registry is an online database that collects information from those affected by all types of frontotemporal degeneration (FTD):
Persons diagnosed, current and former caregivers, family, and friends can join. As a member of the Registry, you can help us advance the science and move faster toward finding treatments and cures. The first step is simple:
AND NOW WE WORK TOGETHER >
Will you join the community working to end FTD?
UPDATES
What We Learn From Every Drop: The Power of Biosamples in FTD
Every biosample holds valuable information that brings us closer to earlier diagnosis and effective treatments for FTD.
Quick Question October 2025 Result:
About 33% reported that they are actively exploring care options …
FTD Research Roundup: What’s New This Fall
The Fall Research Roundup highlights new studies now enrolling people living with FTD, care partners, and biological family members.
What the Registry Community Is Most Interested In
Registry data reveal which FTD subtypes and genes have the highest representation of research-ready participants, helping scientists design stronger, more focused studies.
Alector Announces Results from Phase 3 INFRONT-3 Trial of Latozinemab for FTD-GRN
Alector has announced topline results from its Phase 3 INFRONT-3 trial of latozinemab for FTD-GRN.
- « Previous
- 1
- 2
- 3
- 4
- Next »
What We Learn From Every Drop: The Power of Biosamples in FTD
Every biosample holds valuable information that brings us closer to earlier diagnosis and effective treatments for FTD.
THE FTD REGISTRY IS A PARTNERSHIP OF: